An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.

Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...